Pa Shun International Holdings Limited Overview
| Field | Detail | Source |
|---|---|---|
| Legal name | Pa Shun International Holdings Limited (百信國際控股有限公司) | FY2025 annual results announcement (30 Mar 2026) |
| Former name | Pa Shun Pharmaceutical International Holdings Limited; renamed June 2017 | Company profile (StockAnalysis); irasia.com listing page |
| Incorporated | 3 May 2011, Cayman Islands, exempted company with limited liability | FY2025 results announcement, Note 1 |
| Listing | Main Board, SEHK, 19 June 2015 (IPO of 250 million shares at HK$1.22) | FY2025 results, Note 1; Moomoo company profile |
| Stock code / ISIN | 0574 (HKEX) / KYG693781000 | HKEX filings; Moomoo profile |
| CUSIP | Not applicable / not publicly disclosed | — |
| Registered office | Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111 | FY2025 results, Note 1 |
| HK principal place of business | Suites 2601–2603, 26/F, Shui On Centre, 6–8 Harbour Road, Wanchai, Hong Kong | FY2025 results, Note 1 |
| PRC principal place of business | No. 608–616, Building 28, Longfor North Paradise Walk 2, 229 Wufuqiao East Road, Jinniu District, Chengdu, Sichuan | FY2023 Annual Report, Corporate Information |
| Fiscal year end | 31 December | Filings |
| Presentation currency | RMB (the company's own functional currency is HK$) | FY2025 results, Note 2 |
| Employees | 108 (31 Dec 2025); 97 (2024); 90 (2023); 92 (2022) | FY2025 results; FY2024 results; FY2023 AR |
| Auditor (current) | Forvis Mazars CPA Limited (FY2024, FY2025); previously CCTH CPA Limited (appointed 11 Jan 2017; audited through FY2023) | FY2025 results; FY2023 AR |
| Latest audit opinion (FY2025) | Unmodified, with a material uncertainty related to going concern paragraph | FY2025 results, auditor's report extract |
| Shares in issue | 1,474,992,908 at 31 Dec 2025. About 1,990,576,062 after the June 2026 rights issue (515,583,154 rights shares allotted) | FY2025 results; rights-issue results announcement (17 Jun 2026) |
| Last traded price | HK$0.018 (last close before suspension on 2 Jul 2026) | StockAnalysis (30 Jun 2026 close); etnet quote page |
| Market capitalisation | About HK$35.8 million on post-rights share count (derived: 1,990.6m × HK$0.018). StockAnalysis shows HK$26.55 million using the pre-rights 1.47bn share count — discrepancy noted | Derived; StockAnalysis |
| Trading status | Suspended since 09:00, 2 July 2026 | Resumption-guidance announcement (16 Jul 2026) |
| Controlling shareholder | Mr. Chen Yenfei (陳燕飛), via Praise Treasure Limited (嘉寶有限公司) plus a direct holding. About 1,143.12m shares (≈57.4% derived) after the rights issue. 753.04m of these shares are pledged and subject to a receivership | Rights-issue results (17 Jun 2026); FY2023 AR |
| Website | http://www.pashun.com.cn (also www.pashun.cn) | Filings |
The identification details supplied match the current listed entity. The ticker (0574.HK), ISIN (KYG693781000) and website (pashun.com.cn) are unchanged. The company also uses www.pashun.cn as its investor-relations domain in FY2024–FY2025 results announcements. No change of listing venue has occurred.
Pa Shun International Holdings is a Cayman-incorporated, Hong Kong-listed micro-cap. Its operating business is a small pharmaceutical distribution and manufacturing operation based in Chengdu, Sichuan Province, PRC. The Group reported revenue of RMB86.8 million in FY2025. About 83% came from distributing third-party pharmaceuticals, to wholesalers and to hospitals and medical institutions in rural areas. The remaining 17% came from selling drugs it manufactures in Sichuan. Once a far larger business (RMB845 million revenue in FY2019), the Group has spent five years in a cycle of losses, impairments, bond defaults, trading suspensions, a court-sanctioned creditor scheme (effective March 2024) and a discounted rights issue. It now faces the loss of its operating subsidiaries to secured-creditor receivers and a pending winding-up petition. Its competitive relevance in China's RMB2.6-trillion-plus drug distribution market is negligible. The investment case today is purely a restructuring and recovery-value question rather than an operating one.
Company's own description (FY2025 annual results, paraphrased)
The company describes itself as an investment holding company. Its subsidiaries are principally engaged in pharmaceutical distribution and the manufacture of pharmaceutical products in the PRC. Since FY2023, management has organised and reported the business by business line and distribution channel, as two reportable segments:
Pharmaceutical distribution: Sale of pharmaceutical products to (i) wholesalers and (ii) hospitals and other medical institutions in rural areas.
Pharmaceutical manufacturing: Sale of pharmaceutical products manufactured by the Group.
Revenue is recognised at a point in time on delivery of goods. The chief operating decision makers (the executive directors) assess segments only on revenue and gross profit. No segment asset or liability analysis is provided to them (FY2025 results, Note 3).
In the FY2023 Corporate Governance Report, the company stated a vision of becoming a leading pharmaceutical company by building on its foundation in the PRC (paraphrased).
Independent characterisation
| Customer type | FY2025 revenue (CNY K) | Share of revenue |
|---|---|---|
| Wholesalers (distribution) | 42,427 | 48.9% |
| Rural hospitals and other medical institutions (distribution) | 29,262 | 33.7% |
| Purchasers of self-manufactured products (manufacturing, external) | 15,118 | 17.4% |
| Total | 86,807 | 100% |
Business model. Pa Shun is essentially a regional, sub-scale pharmaceutical trading house with a small captive manufacturing plant. In distribution, it buys drugs from manufacturers and resells them on credit terms of 30–180 days. Its margin is the spread between supplier and customer prices. A key feature is the "agricultural" or rural channel: sales to county- and township-level hospitals and clinics. That channel depends on winning provincial or municipal government tenders for drug supply authority (FY2023 AR, Risk Factors). The manufacturing arm produces generic or traditional products in Sichuan. Its pricing has been cut by inclusion in China's National Centralised Drug Procurement (volume-based procurement, "VBP") programme in 2025 (FY2025 MD&A).
Revenue model mix. 100% product sales (goods), recognised at point in time. There is no service, subscription or licensing revenue. Minor "other income" comes from short-term lease rental (RMB0.9 million in FY2025) and amortisation of government grants (RMB0.5 million) (FY2025 results, Note 4).
Value chain position. The Group is mid-stream, as a distributor and wholesaler. It also has a small upstream manufacturing presence. It has no retail presence today. A self-operated retail pharmacy segment was reported historically (Moomoo company profile lists three segments: distribution, self-operated retail pharmacies and manufacturing). The FY2023 Annual Report lists only two segments; the date the retail segment ceased is not disclosed in the filings reviewed.
Customer types (FY2025).
Source: FY2025 results, Note 3(b)(i): Customer concentration is extreme.
-
In FY2025, Customer C contributed RMB12.1m (14.0%) and Customer D RMB9.5m (10.9%).
-
In FY2024, a single manufacturing customer (Customer A) contributed RMB19.4m (22.4%) and Customer B RMB10.5m (12.1%). Customer A fell below the 10% threshold in FY2025, which coincides with the 41% drop in manufacturing revenue.
-
In FY2023, the top five customers took 59.8% of sales. The top five suppliers provided 73.2% of purchases, and the single largest supplier 43.3% (FY2023 AR, Report of Directors).
End markets. The PRC only. The company states that 100% of segment revenue and results derive from the PRC (FY2025 results, Note 3(b)(iv)). Operations are concentrated in Sichuan Province. The FY2023 AR notes that the main production facilities are all located in Chengdu and Sichuan.
Current operational status (critical). On 2 July 2026, receivers were appointed over the assets of the intermediate holding company of the PRC subsidiaries. The company's 30 September 2026 quarterly update states that these PRC subsidiaries together account for 100% of Group revenue. It also says the company could not adequately access their books and records in time to publish 2026 interim results.
Strategy
Stated strategy themes (paraphrased from FY2023–FY2025 filings)
-
Production and distribution capability. Management repeatedly states it will focus on improving production and distribution capabilities to capture opportunities from a market recovery. This appears in the outlook sections of the FY2023, FY2024 and FY2025 MD&A.
-
Competitive-market framing. In FY2024 and FY2025, management characterises the PRC economy as in a phase of slower, steady development, and expects pharmaceutical wholesale and consumer markets to become more competitive and challenging.
-
Portfolio expansion. The Group says it continues to expand its product portfolio to meet new customer demands (FY2025 going-concern measures). Ten new distribution licences were secured in FY2023.
-
Cost control. Management is tightening operating-expense controls and seeking new business opportunities (FY2025 going-concern measures). Selling expenses fell 42% in FY2025.
-
Balance sheet repair. Measures include the debt restructuring (2023–24 Scheme of Arrangement), refinancing and extension of borrowings, possible pledging of assets (right-of-use assets, property project), and new share issuance (FY2025 going-concern measures; executed as the June 2026 rights issue).
-
Acquisitions and alliances. The FY2023 AR risk section lists "continue to seek for acquisition and alliance" as a strategy. Given the Malaysian episode, this was paired with new investment-management controls.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Target / detail | Status | Source |
|---|---|---|---|---|
| Scheme of Arrangement execution | 2024–2028 | Annual cash payments of the higher of HK$5m (2024) / HK$10m (2025–2028) or a share of net profits; shares to be issued for any shortfall | 2024 payment funded from seized deposit; repayment terms still under negotiation. Default reportedly linked to the July 2026 receivership | FY2025 results Note 12; third-party summary of 2 Jul 2026 announcement |
| Cost-reduction programme | FY2025 | Selling expenses down 42.2% | Achieved | FY2025 MD&A |
| Borrowing extensions | FY2025 – Q1 2026 | RMB19m other borrowings extended; RMB12m bank renewed; RMB10.4m new; RMB5.4m renewed post year-end; RMB13.5m third-party support commitment | Executed | FY2025 going-concern note |
| 1-for-2 non-underwritten rights issue | Proposed 16 Apr 2026; prospectus 11 May 2026; unconditional 10 Jun 2026 | 515,583,154 rights shares issued (69.91% take-up). Gross about HK$6.99m, net about HK$6.49m, entirely for partial loan repayment. Unsubscribed shares under the compensatory placing: none placed | Completed | Rights-issue results (17 Jun 2026) |
| General mandate to repurchase up to 10% | Proposed for 30 Jun 2026 AGM | Up to 221,248,936 shares post-rights | Routine; no buyback executed | itiger summary of 8 Jun 2026 circular |
| Resumption plan | From 14 Jul 2026 | Must satisfy four HKEX conditions by 1 Jan 2028 | In progress; no resumption plan timetable published as of 30 Sep 2026 | 30 Sep 2026 update |
| ESG commitments | — | Reduce electricity use; recycle office materials | Generic; no targets | FY2023 AR |
Medium-term financial targets / guidance
None. The company has not published revenue, margin or leverage targets. There is no investor day and no earnings-call transcript.
Products & Services
Disclosure limitation. The annual results, annual report extracts and interim announcements reviewed do not name individual products, brands, dosage forms, therapeutic categories or approval numbers. A product-by-product catalog is therefore not publicly disclosed in the reviewed sources. What can be stated with evidence is summarised below.
Analytical inference (flagged as inference, not disclosure). The background of the manufacturing head points to traditional Chinese medicine or generics production rather than innovative drugs. Li Xiaoduo graduated in traditional Chinese medicine from Chengdu College of TCM and previously worked as a biotech workshop supervisor. The near-zero R&D disclosure points the same way. VBP inclusion also indicates multi-source generic products.
Product Portfolio
| Segment | Offering | What is disclosed | Target customer | Pricing model | Source |
|---|---|---|---|---|---|
Distribution | Third-party pharmaceutical products (wholesale) | Products sourced from manufacturers and resold. Specific products not named | PRC pharmaceutical wholesalers | Spread-based; 30–180 day credit terms | FY2025 results, Notes 3 and 10 |
Distribution | Third-party pharmaceutical products (rural "agricultural" channel) | Sold to hospitals and medical institutions in rural areas after the Group wins provincial or municipal supply tenders | County, township and rural hospitals and clinics | Tender or government-procurement pricing | FY2023 AR, Risk Factors |
Distribution | 10 newly licensed distribution products (FY2023) | Distribution rights to 10 new products secured in 2023; names not disclosed | Hospital customers | — | FY2023 AR, MD&A |
Manufacturing | Self-manufactured pharmaceutical products | Produced at Chengdu and Sichuan facilities under PRC GMP (2010 revision). A "substantial portion" was included in the 2025 National Centralised Drug Procurement programme | Distributors and institutions; one anchor customer in FY2024 | VBP-set prices for procured items; otherwise not disclosed | FY2025 MD&A; FY2023 AR |
Historical | Self-operated and franchised retail pharmacies | A retail pharmacy segment and franchising entities are referenced in historic disclosures | Retail consumers | Retail | Moomoo profile; FY2023 AR risk section (mentions "self-operating or franchising entities") |
Non-core | Property development project (Chengdu) | Stalled construction project carried at RMB39.9m after cumulative impairments exceeding RMB150m | n/a (asset held) | — | FY2025 results; FY2023 AR |
Non-core | Short-term property leasing | Rental income RMB0.9m (FY2025) | Third-party lessees | Lease | FY2025 results, Note 4 |
“—” = not publicly disclosed.
Financial Narrative
All figures RMB million; fiscal years end 31 December. FY2021–FY2023 are from the FY2023 Annual Report Financial Summary and MD&A. FY2023 balance sheet comparatives follow the FY2024 results announcement. FY2024–FY2025 are from the FY2025 and FY2024 annual results announcements. FY2022 cost-line detail is from the FY2023 AR MD&A.
Income statement
Revenue CAGR. FY2021→FY2025: +0.3% p.a. (derived). FY2019→FY2025: –31.6% p.a. (derived from RMB845.4m to RMB86.8m).
Material non-recurring and non-cash items affecting reported earnings (RMB M)
Sources: FY2023 AR MD&A (FY2021–FY2022 impairments); FY2024 and FY2025 results.
Commentary — income statement
Revenue collapse and plateau. The Group's top line fell by about 90% between FY2019 and FY2021. That period spanned the COVID-19 disruption, the 2019 controlling-shareholder share-pledge crisis and the apparent exit from retail pharmacy. FY2023's rebound to RMB129.4m was attributed to post-COVID normalisation and 10 new distribution licences. It proved temporary: revenue fell back to about RMB86–87m in FY2024–FY2025, which looks like the business's current run-rate.
Gross margin erosion is the key FY2025 inflection. Gross margin fell from 22.6% (FY2023) to 19.7% (FY2024) to 13.8% (FY2025). Management attributes FY2025 to VBP price cuts. Segment data show an equally important channel mix shift toward 4%-margin wholesaler sales. Gross profit of RMB12.0m in FY2025 no longer covers cash overheads: selling plus administrative costs were RMB19.2m.
Cost control is real but insufficient. Selling expenses were cut 42% in FY2025 (advertising fell from RMB2.6m to RMB0.7m). Administrative costs have been held at about RMB14.5m since the FY2023 legal and restructuring spike of RMB23.6m.
Finance costs now consume the business. Finance costs of RMB15.0m in FY2025 exceed gross profit. RMB11.4m of this is non-cash imputed interest unwinding the zero-coupon scheme obligation at a 7.32% effective rate. Cash interest on bank and other borrowings was about RMB3.6m.
Earnings quality is low. FY2023's only profit (RMB2.4m) depended on RMB22.9m of net ECL reversals. FY2025's derived operating loss was held near breakeven (–RMB0.6m) only by an RMB11.6m reversal of trade-receivable ECL. Stripping out ECL movements and impairments, FY2025 underlying EBIT was about –RMB5.8m (derived: 12.0 + 1.3 – 4.6 – 14.6).
Balance sheet
Notes: - Short-term debt (derived) = bank borrowings + current other borrowings + current scheme obligations + current corporate bonds.
-
FY2023 current liabilities are shown as restated in FY2024 comparatives (RMB248.3m). The FY2023 AR shows RMB247.7m.
-
Excluded from debt: deferred government grants (RMB21.0m, non-cash), amounts due to shareholders and related parties (RMB1.2m), and the RMB4.5m payable to the Scheme Administrator (classified in trade and other payables).
-
Gross trade receivables of RMB298.8m carry a RMB246.6m (82.5%) ECL allowance. RMB28.0m of the net balance is aged over six months (FY2025 Note 10).
Cash flow
Operating cash flow figures are from the going-concern notes (FY2024 and FY2025 results). Capex is not disclosed in the announcements reviewed. The company states it did not purchase, sell or redeem listed securities in FY2023–FY2025.
Financing activity (FY2025, from the going-concern note).
-
Other borrowings of about RMB19.0m extended by 1–1.5 years.
-
Bank borrowings of about RMB12.0m renewed for one year.
-
New bank and other borrowings of about RMB10.4m raised.
After the balance-sheet date.
-
RMB5.4m of borrowings renewed.
-
A commitment obtained from an independent third party to provide about RMB13.5m of financial support as needed.
-
The June 2026 rights issue raised gross HK$6.99m (net HK$6.49m), earmarked entirely for partial loan repayment.
Ratios
ROE, ROIC and debt-to-equity are not meaningful because equity has been negative since FY2021. The current ratio is company-reported for FY2022–FY2025; FY2021 is derived. EBITDA used for leverage includes ECL reversals and impairments, so underlying leverage is effectively infinite.
Trend commentary
-
Solvency. The Group has been balance-sheet insolvent (net liabilities) for five consecutive year-ends, and the deficit is widening by about RMB12–20m per year.
-
Liquidity inflection. The 2024 scheme briefly pushed the current ratio above 1.0x by reclassifying debt to non-current. By FY2025 it was back to 0.85x with only RMB5.5m of cash.
-
Working-capital deterioration. FY2025 net trade receivables doubled to RMB52.2m and RMB28.0m is now aged beyond six months. Most of the FY2025 RMB11.6m ECL reversal was booked in distribution, while gross receivables actually rose. Taken together, these points warrant scepticism about the receivable carrying values.
-
Scheme obligations dominate the capital structure. The obligation of RMB160.2m is 78% of total debt (derived). Its maturity profile is back-ended: RMB143.3m falls due in years 2–5, consistent with share issuance to scheme creditors around 2028 if cash payments fall short.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Distribution revenue, external (CNY Mn) | 107.0 | 60.9 | 71.7 |
Distribution to wholesalers (CNY Mn) | — | 21.9 | 42.4 |
Distribution to rural hospitals and institutions (CNY Mn) | — | 38.9 | 29.3 |
Manufacturing revenue, external (CNY Mn) | 22.4 | 25.7 | 15.1 |
Manufacturing inter-segment revenue (CNY Mn) | — | 1.1 | 1.1 |
Total Group revenue (CNY Mn) | 129.4 | 86.6 | 86.8 |
Distribution segment profit, gross profit basis (CNY Mn) | — | 7.4 | 5.8 |
Manufacturing segment profit, gross profit basis (CNY Mn) | — | 9.6 | 6.2 |
Distribution segment margin (%) | — | 12.2 | 8.1 |
Manufacturing segment margin on total segment revenue (%) | — | 36.0 | 38.2 |
Distribution revenue YoY growth (%) | — | -43.1 | 17.7 |
Manufacturing revenue YoY growth (%) | — | 14.6 | -41.1 |
Distribution share of Group revenue (%) | 82.7 | 70.3 | 82.6 |
Manufacturing share of Group revenue (%) | 17.3 | 29.7 | 17.4 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 85.9 | 71.8 | 129.4 | 86.6 | 86.8 |
Revenue YoY growth (%) | -81.9 | -16.4 | 80.3 | -33.1 | 0.3 |
Cost of goods sold (CNY Mn) | — | 58.5 | 100.1 | 69.5 | 74.8 |
Gross profit (CNY Mn) | — | 13.3 | 29.3 | 17.1 | 12.0 |
Gross margin (%) | — | 18.5 | 22.6 | 19.7 | 13.8 |
Selling and distribution expenses (CNY Mn) | — | 6.0 | 7.2 | 8.0 | 4.6 |
Administrative and other operating expenses (CNY Mn) | — | 12.8 | 23.6 | 14.5 | 14.6 |
Finance costs (CNY Mn) | — | 10.6 | 12.9 | 14.8 | 15.0 |
Operating income, derived as PBT plus finance costs (CNY Mn) | — | -32.6 | 16.3 | -0.2 | -0.6 |
D&A, derived as PP&E plus ROU plus intangibles (CNY Mn) | — | — | 3.3 | 3.1 | 3.2 |
EBITDA, derived (CNY Mn) | — | — | 19.6 | 2.9 | 2.5 |
Pre-tax profit (CNY Mn) | -323.4 | -43.2 | 3.4 | -15.0 | -15.7 |
Income tax (CNY Mn) | -7.0 | -0.2 | -1.1 | -0.3 | -0.2 |
Net income attributable (CNY Mn) | -330.4 | -43.4 | 2.4 | -15.3 | -15.9 |
EPS basic (MYR Bn cents) | -22.40 | -2.94 | 0.16 | -1.04 | -1.07 |
EPS diluted (MYR Bn cents) | -22.40 | -2.94 | 0.16 | -1.04 | -1.07 |
Dividend per share (MYR Bn cents) | 0 | 0 | 0 | 0 | 0 |
Operating margin, derived (%) | — | -45.4 | 12.6 | -0.2 | -0.7 |
EBITDA margin, derived (%) | — | — | 15.2 | 3.3 | 2.9 |
Net margin (%) | -384.6 | -60.4 | 1.8 | -17.7 | -18.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Impairment on property development project (CNY Mn) | -111.8 | -17.0 | -9.0 | -4.5 | -3.6 |
Net ECL reversal (provision) on trade receivables (CNY Mn) | — | — | 20.2 | 3.8 | 11.6 |
Net ECL (provision) reversal on other receivables (CNY Mn) | — | — | 2.7 | -5.0 | -1.4 |
Impairment (reversal) on prepayments and deposits (CNY Mn) | — | — | 1.2 | -8.2 | -1.3 |
Gain on restructuring of financial liabilities (CNY Mn) | 0 | 0 | 0 | 17.6 | 0 |
Imputed interest on Scheme obligations (CNY Mn) | 0 | 0 | 0 | 8.9 | 11.4 |
Balance Sheet — Total assets
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 167.2 | 136.1 | 206.6 | 179.6 | 169.7 |
Non-current assets (CNY Mn) | 115.5 | 94.9 | 82.3 | 74.8 | 69.2 |
of which property development project (CNY Mn) | 74.0 | 57.0 | 48.0 | 43.5 | 39.9 |
of which property, plant and equipment (CNY Mn) | — | — | 32.4 | 29.5 | 27.5 |
Current assets (CNY Mn) | 51.8 | 41.2 | 124.3 | 104.9 | 100.5 |
Inventories (CNY Mn) | — | — | 5.4 | 37.8 | 19.7 |
Trade receivables, net of ECL (CNY Mn) | — | — | 27.0 | 26.1 | 52.2 |
Gross trade receivables before ECL (CNY Mn) | — | — | 289.0 | 284.3 | 298.8 |
Prepayments and deposits paid (CNY Mn) | — | — | 65.3 | 21.4 | 16.7 |
Cash and cash equivalents (CNY Mn) | — | 1.9 | 16.5 | 16.0 | 5.5 |
Current liabilities (CNY Mn) | 200.6 | 227.2 | 248.3 | 103.5 | 117.9 |
Non-current liabilities (CNY Mn) | 25.1 | 24.4 | 74.4 | 212.2 | 199.8 |
Bank borrowings (CNY Mn) | — | 4.5 | 7.2 | 11.4 | 19.0 |
Other borrowings (CNY Mn) | — | 21.3 | 75.3 | 32.6 | 26.5 |
Corporate bonds payable (CNY Mn) | — | — | 83.5 | 0 | 0 |
Scheme of Arrangement obligations (CNY Mn) | 0 | 0 | 0 | 163.7 | 160.2 |
Total debt incl. Scheme obligations, derived (CNY Mn) | — | — | 166.0 | 207.7 | 205.7 |
Short-term debt, derived (CNY Mn) | — | — | 115.0 | 22.0 | 34.5 |
Long-term debt, derived (CNY Mn) | — | — | 50.9 | 185.8 | 171.3 |
Net debt, derived (CNY Mn) | — | — | 149.5 | 191.8 | 200.2 |
Goodwill and intangibles (CNY Mn) | — | — | 0.03 | 0.01 | 0 |
Working capital (CNY Mn) | -148.8 | -186.0 | -124.0 | 1.3 | -17.4 |
Total equity / (net deficit) (CNY Mn) | -58.5 | -115.5 | -116.1 | -136.0 | -148.0 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (CNY Mn) | — | — | — | -1.7 | -10.1 |
Dividends paid (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROA on average total assets, derived (%) | -98.6 | -28.6 | 1.4 | -7.9 | -9.1 |
Current ratio (x) | 0.26 | 0.18 | 0.50 | 1.01 | 0.85 |
Net debt to EBITDA, derived (x) | — | — | 7.6 | 66.1 | 80.1 |
Interest coverage, EBIT over finance costs, derived (x) | — | -3.1 | 1.26 | -0.01 | -0.04 |
Asset turnover on average assets, derived (x) | 0.26 | 0.47 | 0.76 | 0.45 | 0.50 |
Days sales outstanding, period-end net, derived (days) | — | — | 76.2 | 110.2 | 219.6 |
Days inventory outstanding, derived (days) | — | — | 19.6 | 198.7 | 95.9 |
Days payables outstanding, trade and bills, derived (days) | — | — | 118.9 | 166.1 | 138.2 |
Cash conversion cycle, derived (days) | — | — | -23.1 | 142.8 | 177.3 |
Revenue by Region and Region Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
PRC revenue (CNY Mn) | 129.4 | 86.6 | 86.8 |
PRC revenue YoY growth (%) | 80.3 | -33.1 | 0.3 |
PRC share of Group revenue (%) | 100 | 100 | 100 |
Hong Kong and other regions revenue (CNY Mn) | 0 | 0 | 0 |
Revenue by Region
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
PRC distribution to wholesalers (CNY Mn) | — | 21.9 | 42.4 |
PRC distribution to rural institutions (CNY Mn) | — | 38.9 | 29.3 |
PRC manufacturing, external (CNY Mn) | 22.4 | 25.7 | 15.1 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price | HK$0.018 (last close before 2 Jul 2026 suspension) | StockAnalysis; etnet |
52-week range (to 30 Jun 2026) | HK$0.016 – HK$0.097 | StockAnalysis |
Shares in issue | About 1,990.6m post-rights (1,474,992,908 pre-rights) | Derived; FY2025 results |
Market cap | About HK$35.8m (derived, post-rights) / HK$26.55m (StockAnalysis, pre-rights count) | Derived; StockAnalysis |
Beta | -0.31 | StockAnalysis |
IPO price (2015) | HK$1.22 | Moomoo profile |
Rights issue price | About HK$0.0136 implied (HK$6.99m ÷ 515.58m shares). etnet lists HK$0.014 | Derived; etnet |
Analyst coverage | None (0 analysts) | Simply Wall St; StockAnalysis |
Share Count (millions)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Weighted average shares, basic (millions) | — | — | 1,475.0 | 1,475.0 | 1,475.0 |
Year-end shares in issue (millions) | 1,475.0 | 1,475.0 | 1,475.0 | 1,475.0 | 1,475.0 |
Share Price & Returns
| Reference point | Price / implied price | Source |
|---|---|---|
IPO, Jun 2015 | HK$1.22 | Moomoo |
Late Apr 2025 (suspension) | Implied about HK$0.037 (market cap HK$54.57m ÷ 1.475bn shares) | TipRanks |
Aug 2025 | Implied about HK$0.057 (market cap HK$84.07m) | TipRanks |
Apr 2026 | About HK$0.046 | etnet |
8 Jun 2026 | HK$0.037 | irasia.com |
30 Jun 2026 | HK$0.018 | StockAnalysis |
Valuation Multiples
| Multiple | Pa Shun |
|---|---|
P/E | n/m (loss-making) |
P/B | n/m (negative equity of RMB148.0m) |
EV (CNY Mn) | About 233 (market cap about 33 + net debt 200.2) |
EV/Sales | About 2.7x |
EV/EBITDA | About 93x (on derived EBITDA of RMB2.5m, which includes ECL reversals) |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | No dividends declared for FY2021–FY2025. Distributable reserves were nil at 31 Dec 2023 (accumulated losses RMB766.9m vs share premium RMB691.9m at company level) |
Dividend policy | Board discretion based on results, cash flow, financial condition and legal restrictions (FY2023 AR) |
Buyback authorisation | General mandate up to 10% proposed for the 30 Jun 2026 AGM (up to 221,248,936 shares); none executed FY2023–FY2025 |
Credit ratings | None. Not rated by Moody's, S&P or Fitch |
Corporate bonds | HK$113.9m issued in 2016–18 at 6.5–7%; defaulted; restructured into the Scheme in 2024 |
Capital Markets — Scheme obligations
| Metric | Within 1 year | 1–2 years | 2–5 years |
|---|---|---|---|
Scheme obligations (CNY Mn) | 8.8 | 8.2 | 143.3 |
Bank borrowings (CNY Mn) | 19.0 | 0 | 0 |
Other borrowings (CNY Mn) | 6.7 | — | — |
Other borrowings, non-current, maturity split not disclosed (CNY Mn) | — | 19.8 | — |
Analyst Conclusions
Management guidance
There is no quantitative guidance. The FY2025 outlook (30 Mar 2026) is qualitative. It expects more competitive and challenging wholesale and consumer pharmaceutical markets, and says the Group will focus on improving production and distribution capabilities. There is no consensus estimate: zero analysts cover the stock.
Bull case (three arguments)
-
Liquidation-to-recapitalisation optionality. HKEX has granted until 1 Jan 2028. A strategic investor could buy into a licensed Sichuan drug manufacturer and distributor with a listed platform. The scheme allows shortfalls to be settled in shares, so dilutive recapitalisation is mechanically available.
-
Asset backing exceeds market cap on a gross basis. PP&E (RMB27.5m), the property project (RMB39.9m), net receivables (RMB52.2m) and inventory (RMB19.7m) total about RMB139m. That compares with an equity value of about RMB33m, although these assets sit behind about RMB206m of debt.
-
Revenue resilience. Revenue held at about RMB86–87m through two crisis years, and there are proven receivable recoveries (RMB11.6m ECL reversal in FY2025). This suggests the PRC operations retain customer franchise if they can be financed.
Bear case (three arguments)
-
Loss of the operating business. Receivers now control the assets of the holding company for 100% of revenue, and management cannot access the subsidiaries' books. Deconsolidation would leave a cash-less listed shell with about RMB160m of scheme obligations.
-
Structural insolvency. FY2025 gross profit (RMB12.0m) does not cover overheads (RMB19.2m) or finance costs (RMB15.0m). Net liabilities widen by about RMB12–20m a year. VBP is a permanent margin headwind.
-
Governance and track record. The company has had four late-results episodes, a disclaimer of opinion, failed related acquisitions proposed by the controller, D&O insurance gaps and three board-composition breaches. Equity holders rank behind secured creditors, scheme creditors and petitioning creditors.
Key catalysts and monitorables (next 12 months)
| Date / window | Catalyst | Why it matters |
|---|---|---|
| 21 Oct 2026 | Adjourned winding-up petition hearing (Underdog Consulting, HK$8m) | A winding-up order would likely end the equity story; dismissal is a resumption condition |
| Q4 2026 | Receivers' actions over Toyot Pa Shun assets: sale, settlement or release | Determines whether the Group keeps its operations |
| By 31 Dec 2026 (indicative) | Next quarterly resumption update (Rule 13.24A) | Disclosure of any resumption plan or investor |
| Ongoing | Appointment of a third INED and audit committee member | Required for Rules 3.10(1) and 3.21 compliance |
| Ongoing | Publication of 2026 interim results (overdue) | Evidence of regained control of records |
| Mar 2027 | FY2026 annual results deadline | Risk of further delay, deconsolidation accounting and audit modification |
| By 30 Jun 2027 | 2026 Scheme yearly payment (HK$10m) | A further default would compound creditor action |
| 1 Jan 2028 | HKEX delisting deadline | Terminal date for resumption |
Concluding analyst verdict
Pa Shun International Holdings has no investment case in the conventional sense. It is a distressed shell whose only economic substance is a small Sichuan pharmaceutical distribution and generic-manufacturing operation, and that operation is now under the control of secured-creditor receivers. Five years of filings tell a consistent story. In FY2019, revenue was RMB845 million. By FY2021 that had collapsed to about RMB86 million, alongside heavy impairments on a stalled Chengdu property project and a failed, controller-originated Malaysian property acquisition. Defaulted retail bonds produced a cascade of winding-up petitions. A 19-month trading suspension followed, and in March 2024 a creditor scheme converted HK$231 million of claims into about RMB160 million of back-ended, zero-coupon obligations.
The scheme bought time but did not fix the economics. FY2025 gross profit of RMB12.0 million covers neither cash overheads nor the unwinding of the scheme liability. Gross margin has compressed to 13.8% under national volume-based procurement and a shift toward 4%-margin wholesale. Cash had fallen to RMB5.5 million by year-end, and equity was negative RMB148 million. The June 2026 rights issue raised under HK$7 million and was 30% unsubscribed: a clear market verdict. Within weeks, a HK$8 million loan default produced a winding-up petition, receivers took over the assets of the intermediate holding company of all revenue-generating subsidiaries, and the shares were suspended.
For equity holders, the realistic outcomes range from heavy dilution in a white-knight recapitalisation, at best, to delisting and liquidation, at worst. The latter is more probable on current evidence. No resumption plan, investor or settlement has been disclosed as of 30 September 2026. Verdict: uninvestable for fundamental investors; relevant only to distressed-debt or shell-value specialists. Key binary event: the 21 October 2026 petition hearing.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Age | Background | Source |
|---|---|---|---|---|---|
Yuan Hongbing (袁紅兵) | Chairman and Executive Director (sole ED) | ED from 28 Mar 2023; Chairman by 20 May 2024 | 46 (per FY2023 AR) | 20+ years in investment, M&A and investment banking. Founder and chairman of Yuanchuang Capital (venture, M&A, restructuring, fund management). ED and CEO of Jintai Energy Holdings (HKEX: 2728) since 2019. ED of China Clean Energy Technology Group (HKEX: 2379), Oct 2022 – Mar 2023 | FY2023 AR; 30 Sep 2026 announcement |
Li Yan (李燕) | Independent Non-Executive Director; Chair of Audit, Remuneration and CG Committees | 10 Mar 2023 | 47 (FY2023 AR) | Accounting bachelor's from Wuhan Institute of Chemical Technology (2000). PRC CPA since 2002. CFO of several listed companies; restructuring and IPO experience | FY2023 AR |
Wong Tung Yuen (王東源) | Independent Non-Executive Director | 20 May 2024 | Not disclosed in reviewed documents | — | FY2024 results |
Board & Management Changes
| Date | Change | Context | Source |
|---|---|---|---|
10 Mar 2023 | INEDs Luo Ke and Ding Qing resign; Li Yan and Khor Khie Liem Alex appointed | Remediation during the 2022–23 suspension | FY2023 AR |
16 Mar 2023 | NED Zhang Xiongfeng resigns | Held 34.8m shares (2.36%) plus 10m options | FY2023 AR |
28 Mar 2023 | Yuan Hongbing appointed ED | Restructuring-oriented investor-executive | FY2023 AR |
1 Oct 2023 | Company secretary changes: So Wing Chun replaced by Lam Yuen Ling Eva (BMI Listed Corporate Services) | Outsourced secretarial function | FY2023 AR |
26 Oct 2023 | ED Shen Shun resigns | Long-serving ED (held 3.5m shares) | FY2023 AR |
22 Feb 2024 | Chairman Xiao Kai, CEO Feng Junzheng, NEDs Zhang Tong and Chen Yunwei, and INED Cao Lei all retire at AGM | Left the board below Listing Rule minimums; no chairman or CEO | FY2023 AR |
20 May 2024 | Ma Qinghai (CEO), Chen Zhongzheng and Zhou Jinkai (NEDs), Lowe Chun Yip and Wong Tung Yuen (INEDs) appear on board; Yuan becomes Chairman | Re-compliance with board composition rules | Board list (20 May 2024); FY2024 results |
26 Jun 2025 | INED Khor Khie Liem Alex retires | — | 2025 Interim Report |
H1 2026 (date not confirmed) | Fang Shuai (房帥) joins as NED | Listed as NED on 26 Jun 2026 | Winding-up petition announcement (26 Jun 2026) |
16 Jun 2026 | Executive director resignation, most likely Ma Qinghai: he is absent from the 26 Jun 2026 director list | Coincides with the rights-issue completion | etnet announcement index; 26 Jun 2026 announcement |
7 Jul 2026 | Directors retire at adjourned AGM. Board reduced to Yuan Hongbing, Li Yan and Wong Tung Yuen (NEDs Chen Zhongzheng, Zhou Jinkai and Fang Shuai, and INED Lowe Chun Yip, no longer listed) | Listing Rule non-compliance announced | etnet index; 16 Jul 2026 announcement director list |
Executive Leadership Team
| Name | Role | Age (FY2023 AR) | Background |
|---|---|---|---|
Li Xiaoduo (李小多) | Manager, manufacturing operations (production and quality control) | 56 | Joined 1998; deputy GM of Wuhan Baixin Holdings Group; formerly with Chengdu Di Kang Pharmaceuticals and Chongqing Oriental Pharmaceutical; TCM graduate, Chengdu College of TCM (1994) |
Tang Zaixiu (唐再秀) | Head of accounting | 45 | Joined Chengdu Kexun in 1999; accounting graduate of Chongqing Technology and Business University (2007) |
Lam Yuen Ling Eva | Company Secretary (outsourced) | — | 30+ years in company secretarial work; director at BMI Listed Corporate Services |
Major Shareholders
| Holder | Shares | % of issued (approx.) | Notes | Source |
|---|---|---|---|---|
Chen Yenfei, via Praise Treasure Limited (嘉寶有限公司) | 1,129,560,000 | 56.7 (derived, post-rights) | Founder and controlling shareholder | Rights-issue results (17 Jun 2026) |
Chen Yenfei, direct | 13,560,000 | 0.7 (derived) | — | Same |
Chen Yenfei total | 1,143,120,000 | 57.4 (derived) | 753,040,000 of these shares are pledged; original chargee's rights assigned to Win Win International Strategic Investment Funds SPC (Win Win Stable No.3 Fund SP); receivers (RSM: Osman Mohammed Arab and Lai Wing Lun) appointed 27 Jul 2022 | FY2023 AR; rights-issue results |
Zhongtai Innovation Capital Management Ltd | 753,040,000 (security interest / investment manager) | 51.05 (pre-rights) | Disclosed as investment manager in respect of the charged shares | FY2023 AR |
Zhang Xiongfeng (former NED) | 34,814,000 | 2.36 (pre-rights, as of FY2023) | — | FY2023 AR |
Public / others | Remainder | about 40 | 24 valid acceptances in the rights issue | Rights-issue results |
Competitive Landscape
Key Competitors
| Competitor | Ticker | Segment overlap | Relative positioning vs Pa Shun |
|---|---|---|---|
Sinopharm Group | 1099.HK | Distribution (national, hospital) | China's largest pharma distributor; dominant hospital network |
Shanghai Pharmaceuticals | 2607.HK / 601607.SH | Distribution and manufacturing | Integrated national player |
China Resources Pharmaceutical | 3320.HK | Distribution and manufacturing | State-backed integrated player |
Jointown Pharmaceutical | 600998.SH | Distribution (including county and rural channels) | Largest private distributor; strong in lower-tier markets, Pa Shun's rural niche |
China Meheco | 600056.SH | Distribution | State-owned distributor |
Huadong Medicine | 000963.SZ | Distribution and manufacturing | Regional (Zhejiang) integrated player |
Sichuan Kelun Pharmaceutical | 002422.SZ | Generic manufacturing (Sichuan) | Major Sichuan-based generic and infusion maker; VBP participant |
Local Sichuan distributors and county-level tender winners (various, unlisted) | — | Rural institutional distribution | Direct competitors for provincial tenders |
Competitor Detail
| Metric | Pa Shun |
|---|---|
Revenue (CNY Mn) | 86.8 |
Revenue growth (%) | 0.3 |
Gross margin (%) | 13.8 |
Net margin (%) | -18.3 |
Recent Developments
--



